Skip to main content
Biosimilars
Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Providing Expanded Access to Prophylaxis and Antineoplastic Therapy in NHL
Read More
Biosimilars
Real-World Utilization of Infliximab and Its Biosimilars in Rheumatoid Arthritis
Read More
Biosimilars
Use of Multibiomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb with EU-Sourced Reference Adalimumab in Patients with Active RA
Read More
Biosimilars
Switching to SB5 Biosimilar from Reference Adalimumab in Patients with RA, Axial Spondyloarthritis, or Psoriatic Arthritis
Read More
Biosimilars
Adalimumab Biosimilar PF-06410293 versus Reference Adalimumab in Patients with Moderate-to-Severe, Active Rheumatoid Arthritis
Read More
Biosimilars
Efficacy and Safety Equivalence of Proposed High-Concentration Adalimumab Biosimilar to Reference Adalimumab in Moderate-to-Severe, Active RA
Read More
Biosimilars
Switching to SB4 versus Continuation of Etanercept Reference in Patients with Rheumatoid Arthritis and Low Disease Activity
Read More
Biosimilars
Impact of Successive Switches of 2 Different Etanercept Biosimilars on Outcomes in Inflammatory Rheumatic Diseases
Read More
Biosimilars
Comparative Safety Analysis of Infliximab with Its Biosimilar Infliximab-dyyb in Pediatric Rheumatic Conditions
Read More
Biosimilars
Multibiomarker Disease Activity Scores as a Biosimilarity Assessment to Compare Biosimilar Infliximab-qbtx with Infliximab-EU in Patients with Active RA
Read More
Page 112 of 198
Results 1111 - 1120 of 1974